In a filing, Denali Therapeutics Inc revealed its President and CEO Watts Ryan J. unloaded Company’s shares for reported $7.43 million on Jul 09 ’25. In the deal valued at $15.00 per share,495,282 shares were sold. As a result of this transaction, Watts Ryan J. now holds 253,071 shares worth roughly $3.67 million.
Then, Watts Ryan J. bought 495,282 shares, generating $7,097,391 in total proceeds.
Before that, Ho Carole sold 12,255 shares. Denali Therapeutics Inc shares valued at $247,796 were divested by the Chief Medical Officer at a price of $20.22 per share. As a result of the transaction, Ho Carole now holds 178,580 shares, worth roughly $2.59 million.
Cantor Fitzgerald upgraded its Denali Therapeutics Inc [DNLI] rating to an Overweight from a a Neutral in a research note published recently. Deutsche Bank began covering DNLI with “Buy” recommendation on February 11, 2025. Robert W. Baird started covering the stock on January 07, 2025. It rated DNLI as “an Outperform”.
Price Performance Review of DNLI
On Friday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock fall -5.41% to $14.52. Over the last five days, the stock has lost -1.16%. Denali Therapeutics Inc shares have fallen nearly -30.73% since the year began. Nevertheless, the stocks have fallen -28.75% over the past one year. While a 52-week high of $33.33 was reached on 02/05/25, a 52-week low of $10.57 was recorded on 04/07/25.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 14.15, which if violated will result in even more drops to 13.78. On the upside, there is a resistance level at 15.12. A further resistance level may holdings at 15.72.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2025-06-13, dropping by -0.15 million shares to a total of 11.95 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 12.1 million shares. There was a decline of -1.3%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 03, 2025 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating .
